When was PROSYS acquired by IMA GROUP?

PROSYS was acquired by IMA GROUP in 2026.

What was the revenue of PROSYS at the time of the deal?

The revenue of PROSYS at the time of the deal is estimated to be in the range of 1b - 3b EUR.

What was the EBITDA of PROSYS during the acquisition?

PROSYS's EBITDA is estimated to be in the range of 250M - 500M EUR.

How is the data for the PROSYS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the PROSYS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://ima.it/en/ima-acquires-prosys/

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaPROSYS

02/2026

PROSYS acquired by IMA GROUP

IRELAND Life Sciences / Medical Devices REV 1b - 3b EUR

Context

IMA Group acquired a majority stake in ProSys Sampling Systems Limited from its co-founder and Treysa Limited. The transaction is a core component of IMA's international growth strategy, aiming to strengthen its "IMA Life" division by integrating specialized containment and sampling expertise. ProSys will continue to operate as an independent business from its headquarters in Ireland, with Michael McLoughlin remaining as Managing Director. This acquisition follows IMA's August 2024 purchase of Sarong's packaging divisions, further consolidating IMA's leadership in the advanced biopharmaceutical technology segment.

PROSYS, which reported an EBITDA margin of in 2025, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

ProSys is a leading global supplier of specialized aseptic and containment isolator technology and sampling systems. Founded in 1997, the company designs and manufactures "Engineered to Order" (EtO) systems for the safe handling of highly potent compounds, serving biopharmaceutical giants like Pfizer, GSK, and Eli Lilly.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
03/2026	Abbott Laboratories	Exact Sciences	UNITED STATES	Diagnostic Equipment
03/2026	RESONETICS	RESOLUTION MEDICAL	UNITED STATES	Medical Devices
02/2026	NORD HOLDING	HALLMARQ VETERINARY IMAGING	UNITED KINGDOM	Diagnostic Equipment
02/2026	VIVO CAPITAL	DUTSCHER	FRANCE	Medical Consumables
02/2026	CIMG	DAREN TECHNOLOGY	CHINA	R&D Biotech
01/2026	ARDIAN	IVB Wellness Lab	SPAIN	Nutrition & Dietary Supplements
01/2026	YOTTA CAPITAL	VILLARD	FRANCE	Medical Consumables
01/2026	FAGRON	UNIVERSITY COMPOUNDING PHARMACY (UCP)	UNITED STATES	Compounding
12/2025	MONTAGU PRIVATE EQUITY / Kohlberg	Teleflex Medical OEM	UNITED STATES	Medical Consumables
12/2025	CHARTERHOUSE	WINBACK	FRANCE	Medical Devices

REFERENCES

Revenue range: 1b - 3b EUR

EBITDA range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PROSYS by IMA GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: ima group